Your browser of choice has not been tested for use with If you have issues, please download one of the browsers listed here.

Astrazeneca Plc (AZN) NYSE

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart


See More
  • Market Capitalization, $K 70,625,096
  • Shares Outstanding, K 2,530,040
  • Annual Sales, $ 24,708 M
  • Annual Income, $ 2,825 M
  • 36-Month Beta 0.78
  • Price/Sales 2.97
  • Price/Book 4.74

Price Performance

See More
Period Period Low Period High Performance
26.86 +0.35%
on 01/20/17
28.81 -6.44%
on 01/10/17
-0.35 (-1.30%)
since 12/23/16
25.55 +5.50%
on 12/07/16
30.27 -10.95%
on 10/24/16
-3.76 (-12.26%)
since 10/21/16
25.55 +5.50%
on 12/07/16
35.04 -23.07%
on 08/05/16
-4.52 (-14.37%)
since 01/22/16

Most Recent Stories

More News
Blog Coverage AbbVie Received FDA Approval for Treatment for Marginal Zone Lymphoma

Upcoming AWS Coverage on AstraZeneca This Could Be the Biggest Winner of 2017's Biotech Boom Market Commentary: The catalysts for a major biotech rally in 2017 are already multiplying-not least because of the Trump presidential victory-and one little-known company is poised for huge...

AstraZeneca Offers Update on Immuno-Oncology Program

AstraZeneca (AZN) provided an update on its late-stage immuno-oncology program for first-line NSCLC. Life-Saving Device Could Transform the Medical Market in 2017 Market Commentary: A little-known biotech company is poised to potentially earn millions in revenue with the planned upcoming release of a breakthrough technology that could prevent massive...

Can AstraZeneca (AZN) Be a Solid Choice for Value Investors?

Let's see if AstraZeneca (AZN) stock is a good choice for value-oriented investors right now from multiple angles.

The FDA Approved Fewer Drugs in 2016: Here's Why

Was there any specific reason for the significantly lower number of drug approvals in 2016 compared to 2015?

Pharma Stock Roundup: PCSK9 Inhibitor Praluent in News, Allergan's Preliminary 2017 View

Key highlights this week include a court injunction blocking sales of PCSK9 inhibitor Praluent and preliminary guidance from Allergan (AGN).

Pharma Stock Roundup: Cempra Plunges to 52-Week Low, Shire Drug Label Expanded

Key highlights this week include complete response letters from the FDA for a couple of companies with Cempra (CEMP) plunging to a 52-week low.

Blog Coverage Ionis Pharma Records Three Milestones Payment Within a Week

Upcoming AWS Coverage on Merus Labs International Post-Earnings Results

Pfizer Ibrance sNDA Accepted by FDA under Priority Review

Pfizer Inc.'s (PFE) supplemental new drug application (sNDA) to convert accelerated approval for its breast cancer drug, Ibrance, to regular approval was accepted by the FDA under priority review.

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development,...

See More

Support & Resistance

2nd Resistance Point 27.68
1st Resistance Point 27.37
Last Price 27.01
1st Support Level 26.81
2nd Support Level 26.56

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.